Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NASDAQ:INNV NASDAQ:LFST NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$52.49+1.2%$43.64$7.57▼$63.06$2.20B0.72845,951 shs732,135 shsINNVInnovAge$4.95+6.9%$3.90$2.60▼$6.69$628M0.5241,955 shs34,988 shsLFSTLifeStance Health Group$5.38+2.9%$4.88$3.74▼$8.61$2.03B1.172.03 million shs1.79 million shsVCYTVeracyte$33.93-0.5%$28.44$22.61▼$47.32$2.68B2.07952,005 shs1.32 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+1.18%-4.68%+0.13%+332.02%+253.47%INNVInnovAge+6.91%-0.60%+32.35%+22.52%-16.95%LFSTLifeStance Health Group+2.87%+3.86%-3.06%+5.91%-21.00%VCYTVeracyte-0.53%+6.46%+9.45%+26.23%-2.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$52.49+1.2%$43.64$7.57▼$63.06$2.20B0.72845,951 shs732,135 shsINNVInnovAge$4.95+6.9%$3.90$2.60▼$6.69$628M0.5241,955 shs34,988 shsLFSTLifeStance Health Group$5.38+2.9%$4.88$3.74▼$8.61$2.03B1.172.03 million shs1.79 million shsVCYTVeracyte$33.93-0.5%$28.44$22.61▼$47.32$2.68B2.07952,005 shs1.32 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+1.18%-4.68%+0.13%+332.02%+253.47%INNVInnovAge+6.91%-0.60%+32.35%+22.52%-16.95%LFSTLifeStance Health Group+2.87%+3.86%-3.06%+5.91%-21.00%VCYTVeracyte-0.53%+6.46%+9.45%+26.23%-2.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.00Buy$56.507.64% UpsideINNVInnovAge 1.50Reduce$5.001.01% UpsideLFSTLifeStance Health Group 2.86Moderate Buy$8.5057.99% UpsideVCYTVeracyte 2.70Moderate Buy$40.9020.54% UpsideCurrent Analyst Ratings BreakdownLatest INNV, VCYT, CELC, and LFST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025CELCCelcuityGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/18/2025INNVInnovAgeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$5.008/18/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $66.008/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$74.00 ➝ $70.008/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetUnderweight$28.008/8/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.50 ➝ $9.007/28/2025CELCCelcuityLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$28.00 ➝ $60.007/28/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $50.007/28/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$29.007/25/2025LFSTLifeStance Health GroupBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2025CELCCelcuityStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 9/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$3.11 per shareN/AINNVInnovAge$853.70M0.79N/AN/A$1.76 per share2.81LFSTLifeStance Health Group$1.25B1.67$0.04 per share131.89$3.78 per share1.42VCYTVeracyte$445.76M5.99$1.03 per share32.90$15.17 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$111.78M-$3.45N/AN/AN/AN/A-150.07%-64.67%11/13/2025 (Estimated)INNVInnovAge-$30.31M-$0.23N/A82.50N/A-3.55%-12.02%-5.73%11/4/2025 (Estimated)LFSTLifeStance Health Group-$57.44M-$0.05N/AN/AN/A-1.23%-1.11%-0.76%11/6/2025 (Estimated)VCYTVeracyte$24.14M$0.33102.8247.13N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest INNV, VCYT, CELC, and LFST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/9/2025Q4 2025INNVInnovAge-$0.02-$0.01+$0.01-$0.01$219.80 million$221.42 million8/14/2025Q2 2025CELCCelcuity-$0.90-$1.04-$0.14-$1.04N/AN/A8/7/2025Q2 2025LFSTLifeStance Health Group-$0.03-$0.01+$0.02-$0.01$345.05 million$345.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AINNVInnovAgeN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity2.244.584.58INNVInnovAge0.271.071.07LFSTLifeStance Health Group0.191.481.48VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%INNVInnovAge12.26%LFSTLifeStance Health Group85.50%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCELCCelcuity15.78%INNVInnovAge1.40%LFSTLifeStance Health Group6.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4042.43 million35.73 millionOptionableINNVInnovAge2,440135.64 million133.74 millionOptionableLFSTLifeStance Health Group10,218388.94 million363.27 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionableINNV, VCYT, CELC, and LFST HeadlinesRecent News About These CompaniesContrasting Veracyte (NASDAQ:VCYT) & OPKO Health (NASDAQ:OPK)5 hours ago | americanbankingnews.comAssenagon Asset Management S.A. Raises Stock Holdings in Veracyte, Inc. $VCYTSeptember 22 at 4:08 AM | marketbeat.comExchange Traded Concepts LLC Purchases 23,047 Shares of Veracyte, Inc. $VCYTSeptember 21 at 4:12 AM | marketbeat.comStrs Ohio Takes Position in Veracyte, Inc. $VCYTSeptember 20 at 3:04 AM | marketbeat.comAQR Capital Management LLC Lowers Stock Position in Veracyte, Inc. $VCYTSeptember 15, 2025 | marketbeat.comVeracyte, Inc. $VCYT Stake Trimmed by Great Lakes Advisors LLCSeptember 13, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) CEO Sells 7,667 SharesSeptember 10, 2025 | marketbeat.comVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingSeptember 10, 2025 | finance.yahoo.comVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comMarc Stapley Sells 7,667 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 9, 2025 | insidertrades.comVeracyte, Inc. $VCYT Stake Lifted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comBridgeway Capital Management LLC Sells 41,300 Shares of Veracyte, Inc. $VCYTSeptember 8, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 172,010 Shares of Veracyte, Inc. $VCYTSeptember 6, 2025 | marketbeat.comPDT Partners LLC Sells 27,566 Shares of Veracyte, Inc. $VCYTSeptember 5, 2025 | marketbeat.comMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINNV, VCYT, CELC, and LFST Company DescriptionsCelcuity NASDAQ:CELC$52.49 +0.61 (+1.18%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$52.84 +0.35 (+0.68%) As of 08:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.InnovAge NASDAQ:INNV$4.95 +0.32 (+6.91%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$4.94 0.00 (-0.10%) As of 09/22/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.LifeStance Health Group NASDAQ:LFST$5.38 +0.15 (+2.87%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$5.36 -0.02 (-0.37%) As of 06:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Veracyte NASDAQ:VCYT$33.93 -0.18 (-0.53%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$33.90 -0.03 (-0.09%) As of 08:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
